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The effects induced by exogenous manipulation of endocannabinoid neurotransmission
on emotion and memory are often contradictory. Among the different factors involved, of
particular interest is the binding affinity of endocannabinoids, and their analogs, for other
receptor families beyond cannabinoid receptors, such as the peroxisome proliferator-
activated receptors (PPARs), and the transient receptor potential cation channel
subfamily V member 1 (TRPV1). The aim of this study was to investigate which receptor
subtype mediates cannabinoid effects on memory consolidation for emotionally arousing
experiences. We tested two cannabinoid compounds with different pharmacological
properties in the inhibitory avoidance task, and evaluated whether the observed effects
are mediated by cannabinoid, PPARα or TRPV1 receptor activation. We found that
the synthetic cannabinoid agonist WIN55,212-2 and the FAAH inhibitor URB597 both
enhanced memory consolidation for inhibitory avoidance training. WIN55,212-22 effects
on memory consolidation were predominantly mediated by CB1 receptor activation but
CB2 receptors were involved as well. The URB597-induced memory enhancement was
dependent on the activation not only of CB1 and CB2 receptors but, notwithstanding,
PPAR-α and TRPV1 receptors were involved as well. Our findings drive beyond
the classical hypothesis centered on the unique role of CB1 receptor activation for
cannabinoid effects on memory, and reveal new insights in the neural mechanisms of
memory consolidation.
Keywords: endocannabinoid system, inhibitory avoidance, WIN55,212-2, URB597, memory retention, emotional
arousal
INTRODUCTION
It is known that cannabis users may experience euphoria, feelings of relaxation, altered perception
of time, and increased appetite. Conversely, other users experience anxiety, fear, distrust, or panic
(Mason and McBay, 1985; Thornicroft, 1990; Pope and Yurgelun-Todd, 1996; Huestis, 2002).
Given the widespread distribution of cannabinoid receptors in many brain areas embodying
the cortico-limbic system (e.g., prefrontal cortex, hippocampus, cerebellum, striatum, amygdala)
(Katona et al., 2001; Mackie, 2005; Svizenska et al., 2008), it is not surprising that cannabinoids
modulate emotional responses and emotional states, as well as cognitive and memory processes.
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Substantial evidence from both animal research and human
studies showed that cannabinoids exert significant effects
on attention and learning and memory, causing long-term
modifications (Antonelli et al., 2005; Chhatwal et al., 2005;
Quinn et al., 2008; Schweinsburg et al., 2008; Rubino et al.,
2009; Campolongo et al., 2011; Batalla et al., 2013; Verrico
et al., 2014). With regard to memory function, some reports
showed disruptive effects (Riedel and Davies, 2005; Ranganathan
and D’Souza, 2006; Solowij and Battisti, 2008), while others
reported no evidence of cannabinoid-related deficits (Pope and
Yurgelun-Todd, 1996; Solowij et al., 2002; Kanayama et al.,
2004; Fisk and Montgomery, 2008). Contrasting findings on the
behavioral effects induced by exogenous manipulation of the
endocannabinoid signaling also arise from several preclinical
studies (Morena and Campolongo, 2014). For instance, it has
been shown that both cannabinoid agonists and antagonists
exert in some studies anxiogenic-like effects, and anxiolytic-
like effects in others regardless of their pharmacological action
(Haller et al., 2004a,b; Moreira et al., 2006, 2009; Morena
et al., 2016). Moreover, low versus high doses of cannabinoid
agonists often induce opposite effects (e.g., anxiolytic versus
anxiogenic effects) (Moreira and Wotjak, 2010), which were not
reversed by cannabinoid receptor sub-type 1 (CB1) antagonists
(Haller et al., 2007). Other in vivo studies demonstrated
that administration of the non-selective cannabinoid receptor
agonist WIN55,212-2 facilitates the consolidation of inhibitory
avoidance memory, and the extinction of fear and spatial memory
(Chhatwal et al., 2005; Pamplona et al., 2006; Campolongo et al.,
2009b) while it impairs contextual fear conditioning acquisition
(Pamplona and Takahashi, 2006), as well as consolidation
and retrieval of spatial memory in rats (Yim et al., 2008;
Morena et al., 2015). Administration of the endocannabinoid
transporter inhibitor AM404 disrupted prepulse inhibition and
enhanced the startle response but impaired memory recognition
(Fernandez-Espejo and Galan-Rodriguez, 2004; Campolongo
et al., 2012). On the other hand, increased anandamide signaling
through inhibition of its metabolizing enzyme FAAH by
URB597 treatment, enhanced consolidation and reconsolidation
of aversive memories (Morena et al., 2014; Ratano et al.,
2014).
One possible explanation for such contrasting results could
lie on the fact that cannabinoid receptors are expressed at
both glutamatergic and GABAergic synapses, which often exert
opposite effects on cognition and emotions (Ruehle et al.,
2012). Discrepant findings could also be due to differences
in the expression, distribution and functional characteristics
of cannabinoid receptors (Callen et al., 2012), as well as to
activation of distinct neuronal circuits depending upon the
complexity of the behavioral tasks used. Moreover, the effects
induced by pharmacological manipulation of endocannabinoid
neurotransmission are strongly influenced by environmental and
experimental conditions (Zanettini et al., 2011; Campolongo
et al., 2012; Manduca et al., 2014; Morena and Campolongo,
2014). Similarly, the time of drug administration should be
considered as a further confounding factor, as pre- versus
post-training, and pre- versus post-retrieval administration may
influence distinctive memory functions (i.e., memory acquisition,
consolidation, retrieval or extinction) (Morena and Campolongo,
2014). In particular, pre-training administration may affect
several other parameters such as pain sensitivity and motivation,
among several others, rather than memory functions per se
leading to a wrong interpretation of the obtained results.
Until now the cognitive effects induced by cannabinoids
drugs have been considered to be dependent only on CB1
activation, overlooking a possible involvement of CB2 receptors.
Traditionally, CB2 receptors have been thought to be exclusively
expressed in the cells of the immune system (Munro et al., 1993).
Despite their expression in neurons is still controversial, growing
evidence strongly suggests that CB2 receptors are also expressed
in the brain, and that they are involved in several neurobiological
functions (Gong et al., 2006; Onaivi et al., 2006; Brusco et al.,
2008; Garcia-Gutierrez et al., 2012; Navarrete et al., 2012; Li and
Kim, 2016). Noteworthy, endocannabinoids, and their analogs,
show binding affinity for other receptor families beyond the
cannabinoid receptors, including the peroxisome proliferator-
activated receptors (PPARs) (Fu et al., 2003; Bouaboula et al.,
2005; O’Sullivan, 2007; Campolongo et al., 2009a; Luchicchi et al.,
2010), and the transient receptor potential channels, especially
vanilloid receptors transient receptor potential cation channel
subfamily V member 1 (TRPV1) (Zygmunt et al., 1999; Di Marzo
and De Petrocellis, 2010). PPARs are family of a nuclear hormone
receptor (PPAR-α, PPAR-β/δ, and PPAR-γ) which regulate
several biological functions such as lipid homeostasis (Friedland
et al., 2012; Menendez-Gutierrez et al., 2012; Neher et al., 2012;
Poulsen et al., 2012; Alexander et al., 2015). Particularly, PPAR-
α is expressed in the hippocampus and regulates the expression
of neuronal cAMP-response-element binding protein (CREB),
a key regulator of memory formation (Roy et al., 2013, 2015).
Consistently, PPAR-α knockout mice showed an impairment in
hippocampal-dependent memory and in spatial learning.
Transient receptor potential cation channel subfamily V
member 1 is a calcium-permeable cation channel known to
be involved in regulating both long-term potentiation (LTP)
and long-term depression (LTD) in the hippocampus (Marsch
et al., 2007; Li et al., 2008; Chavez et al., 2010; Bennion et al.,
2011). Moreover, mice lacking TRPV1 receptors showed reduced
freezing response in the auditory fear conditioning as well as
reduced anxiety-like behaviors compared to wild-type (Marsch
et al., 2007). On the other hand, activation of TRPV1 locally into
the hippocampus counteract the deleterious effects of stress on
spatial memory retrieval (Li et al., 2008).
Therefore, the aim of the present study was to investigate the
effects induced by cannabinoid compounds with different target
selectivity on memory consolidation for aversive experiences,
and to determine whether such effects are solely mediated
by CB1 receptors, or if other non-CB1 targets might also be
involved. Rats were trained in an inhibitory avoidance task,
and the impact of any possible confounding variable has been
reduced to the minimum by using the identical behavioral setting
for any tested drug (e.g., animals were all tested in the same
behavioral equipment at the same time of the day and all equally
handled, drugs were all dissolved in an identical vehicle). To
selectively test the effects on memory consolidation, all drugs
were systemically administered post-training. Thereafter, we
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evaluated the involvement of different receptors, such as the
PPAR-α, TRPV1 or CB2 receptors, and not only the classic CB1
activation in mediating the effects of the tested drugs on memory.
EXPERIMENTAL PROCEDURES
Animals
Male adult Sprague-Dawley rats (total n = 499; 350–450 g at the
time of training; Charles River Laboratories, Calco, Italy) were
housed individually and maintained in a temperature-controlled
environment (20± 1◦C) under a 12-h light/12-h dark cycle (7:00
AM to 7:00 PM lights on) with unlimited access to food and
water. All procedures involving animal care or treatments were
approved by the Italian Ministry of Health (Rome, Italy) and
performed in compliance with the guidelines of the Directive
2010/63/EU of the European Parliament, and the D. L. 26/2014
of Italian Ministry of Health.
Drug Treatments
The cannabinoid receptor agonist WIN55,212-2 [R(+)-
[2,3-dihydro-5-methyl-3-[(morpholinyl) methyl] pyrolol [1,2,3
-de]-1,4-benzoxazin-yl]-(1-naphthalenyl) methanone mesylate]
(0.3, 1, and 3 mg/kg); the FAAH inhibitor URB597 [(3′-(amino-
carbonyl)[1,1′-biphenyl]-3-yl)-cyclohexylcarbamate] (0.1, 0.2,
and 0.3 mg/kg); the CB1 receptor antagonist SR14
1716 [5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-
1-piperidinyl-1H-pyrazole-3-carboxamide] (0.3, 1, and 3 mg/kg);
the CB2 receptor antagonist SR144528 [5-(4-chloro-3-
methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3
-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide]
(0.03, 0.1, and 0.3 mg/kg); the PPAR-α receptor
antagonist GW6471 [N-[(2S)-2-[[(1Z)-1-methyl-3-oxo-3-
[4-(trifluoromethyl)phenyl]-1-propen-1-yl]amino]-3-[4-[2-(5-
methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]propanamide]
(1, 2, and 4 mg/kg, Tocris Bioscience), capsazepine (5 mg/kg,
Tocris Bioscience) were administered by intraperitoneal
injection in a volume of 1 ml/kg immediately after the
training trial. Drug solutions, freshly prepared before each
experiment, were dissolved all in the same vehicle containing 5%
polyethylene glycol, 5% Tween-80 and 90% saline. WIN55,212-2,
URB597, SR141716, SR144528 were granted by the NIMH
Chemical Synthesis and Drug Supply Program. Time for
drug administration has been chosen on the basis of our
preliminary findings or literature data taking into account the
pharmacokinetic properties of all drugs (Lichtman et al., 1995;
Bridges et al., 2001; Capasso et al., 2001; Da and Takahashi, 2002;
Pamplona and Takahashi, 2006; Morgese et al., 2007; Russo et al.,
2007; Butler et al., 2008; Sagar et al., 2008; Campolongo et al.,
2009a; Polissidis et al., 2009; Costa et al., 2010; Adamczyk et al.,
2012; Scuderi et al., 2014).
Inhibitory Avoidance Apparatus and
Procedure
Rats were trained and tested in an inhibitory avoidance apparatus
consisting of two compartments, separated by a sliding door.
The starting compartment (31 cm long), made of opaque white
plastic, was illuminated by a lamp; the shock compartment (60 cm
long), made of two dark, electrifiable metal plates, was not
illuminated (McGaugh et al., 1988). Training and testing were
performed during the light phase, between 10:00 AM and 2:00
PM, and were conducted in dim light conditions in a sound-
attenuated room. Animals were handled 1 min each for 3 days
prior to the training day.
The behavioral procedure was performed as previously
described (Morena et al., 2014). Briefly, for training, the rats
were placed into the starting compartment of the apparatus,
facing away from the door, and were permitted to explore
the apparatus. After the rats stepped completely into the
dark compartment, the sliding door was closed and a single
inescapable footshock was delivered (0.35 mA, 1 s). Fifteen
seconds after termination of the footshock the animals were
removed from the shock compartment. Retention was tested
48 h later. On the retention test trial, the rats were placed
into the starting compartment and the latency to reenter the
shock compartment was recorded (cut-off 600 s) and used as a
measure of memory retention. Longer latencies were interpreted
as indicating better memory retention (Dawson and McGaugh,
1971). Between each session the apparatus was cleaned with a
70% ethanol solution.
Statistical Analysis
Data were analyzed using ANOVA with treatment as the
between-subject factor using standard statistical software (SPSS
23.0). To determine whether learning had occurred, paired t-tests
were used to compare the training and retention latencies of
the vehicle groups. The source of the detected significances was
determined by Tukey–Kramer’s post hoc tests. Ps < 0.05 were
considered statistically significant. The number of rats per group
is indicated in the figures. Data are expressed as mean± SEM.
RESULTS
Effect of Post-training Administration of
WIN55,212-2 on Inhibitory Avoidance
Retention Performances
In this experiment we examined whether the non-selective
cannabinoid receptor agonist WIN55,212-2, administered
immediately after the training of the inhibitory avoidance
task, would affect retention performance at testing. Average
step-through latencies for all groups during the training, before
footshock and drug administration, were 13.70± 1.25 s. One-way
ANOVA for training latencies revealed no significant differences
among groups (F3,42 = 1.45, p = 0.24). At testing, retention
latencies of rats given vehicle immediately after the training were
significantly longer than their approach latencies during the
training trial (t = 2.53, p = 0.03), showing that vehicle treated
rats correctly retained the memory of the footshock received
during the training.
Retention latencies analyzed by one-way ANOVA revealed a
significant treatment effect (F3,42 = 3.44, p = 0.03). Post hoc
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analysis indicated that rats administered with WIN55,212-2
at the dose of 1 mg/kg had retention latencies significantly
longer than vehicle-treated rats (p < 0.05; Figure 1A), thus
showing that the non-selective cannabinoid receptor agonist
WIN55,212-2 enhanced memory consolidation of inhibitory
avoidance training.
Effect of Post-training Administration of
URB597 on Inhibitory Avoidance
Retention Performances
In this experiment we examined whether enhancing anandamide
signaling at active synapses, by administering the FAAH enzyme
inhibitor URB597 immediately after the training of the inhibitory
avoidance task, would affect retention performance at testing.
Average step-through latencies for all groups during the training,
before footshock and drug administration, were 12.91 ± 1.24 s.
One-way ANOVA for training latencies revealed no significant
differences among groups (F3,44 = 1.25, p= 0.30).
At testing, retention latencies of rats given vehicle were
significantly longer than their approach latencies during the
training trial (t = −2.45, p = 0.03), showing that the rats
retained the memory of the footshock. Retention latencies
analyzed by one-way ANOVA revealed a significant treatment
effect (F3,44 = 4.01, p = 0.01). Post hoc analysis indicated that
rats administered with URB597, at the dose of 0.2 mg/kg, had
retention latencies significantly longer than vehicle-treated rats
(p < 0.05; Figure 1B), thus showing that enhancing anandamide
tone at active synapses enhanced memory consolidation of
aversive training.
Effect of Post-training Administration of
Cannabinoid Receptor Antagonists on
Inhibitory Avoidance Retention
Performances
In a first experiment we examined whether blocking CB1 receptor
signaling by administering the CB1 receptor antagonist SR141716
immediately after the training of the inhibitory avoidance task
would affect retention performance at testing. Average step-
through latencies for all groups during the training, before
footshock and drug administration, were 12.60± 1.49 s. One-way
ANOVA for training latencies revealed no significant differences
among groups (F3,39 = 1.62, p= 0.20).
At testing, retention latencies of rats given vehicle immediately
after the training were significantly longer than their approach
latencies during the training trial (t=−4.25, p< 0.001), showing
that the rats retained the memory of the footshock.
Retention latencies analyzed by one-way ANOVA did not
reveal a significant treatment effect (F3,39 = 0.06, p = 0.98;
Figure 2A), thus showing that blocking CB1 receptor signaling
did not affect memory consolidation for aversive events.
In a second experiment we examined whether blocking CB2
receptor signaling by administering the CB2 receptor antagonist
SR144528 immediately after the training of the inhibitory
avoidance task would affect retention performance at testing.
Average step-through latencies for all groups during the training,
before footshock and drug administration, were 15.05 ± 1.59 s.
One-way ANOVA for training latencies revealed no significant
differences among groups (F3,43 = 1.59, p = 0.21; Figure 2B).
At testing, retention latencies of rats given vehicle immediately
after the training were significantly longer than their approach
latencies during the training trial (t = −2.62, p = 0.03),
showing that the rats retained the memory of the footshock
received during the training. Retention latencies analyzed by
one-way ANOVA did not reveal a significant treatment effect
(F3,40 = 1.62, p= 0.20), thus showing that blocking CB2 receptor
signaling did not affect memory consolidation for aversive events.
However, it should be noted that although it is not statistically
significant, SR144528 at the dose of 0.1 mg/kg, tends to impair
memory retention (Figure 2B).
Effect of Post-training Administration of
GW6471 on Inhibitory Avoidance
Retention Performances
In this experiment we examined whether blocking PPAR-α
receptor signaling by administering the PPAR-α antagonist
GW6471 immediately after the training of the inhibitory
avoidance task would affect retention performance at testing.
Average step-through latencies for all groups during the training,
before footshock and drug administration, were 14.54 ± 1.43 s.
One-way ANOVA for training latencies revealed no significant
differences among groups (F3,38 = 1.37, p = 0.27; Figure 2C).
At testing, retention latencies of rats given vehicle immediately
after the training were significantly longer than their approach
latencies during the training trial (t = −3.37, p = 0.01),
showing that the rats retained the memory of the footshock
received during the training. Retention latencies analyzed by
one-way ANOVA did not reveal a significant treatment effect
(F3,38 = 0.19, p = 0.90), thus showing that blocking PPAR-
α receptor signaling did not affect memory consolidation for
aversive events.
Enhancement of Inhibitory Avoidance
Retention Performances Induced by
WIN55,212-2 Requires Concomitant
Activation of both CB1 and CB2
Receptors
In these experiments we examined whether the enhancing
effect on memory consolidation induced by WIN55,212-2
could depend on activation of CB1 or CB2 receptors. First, we
co-administered immediately after the training of the inhibitory
avoidance the memory-modulating dose of WIN55,212-2
(1 mg/kg) with SR141716 (0.3 mg/kg). Average step-through
latencies for all groups during the training, before footshock and
drug administration, were 13.27 ± 1.37 s. One-way ANOVA
for training latencies revealed no significant differences among
groups (F3,34 = 0.58, p= 0.63).
At testing, retention latencies of vehicle-treated rats were
significantly longer than their approach latencies during the
training trial (t =−2.24, p= 0.49), showing that the rats retained
the memory of the footshock received during the training.
Interestingly, retention latencies analyzed by two-way ANOVA
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FIGURE 1 | Effects of post-training administration of WIN55,212-2 or URB597 on retention latencies in the inhibitory avoidance task. WIN55,212-2
1 mg/kg (A) and URB597 0.2 mg/kg (B) increased retention latencies showing a facilitation of memory retention. Data represent mean ± SEM. ∗p < 0.05 vs.
vehicle-treated rats; #p < 0.05 vs. URB597-treated rats (n = 11–13 per group).
FIGURE 2 | Effects of post-training administration of CB1 or CB2 or PPAR-α antagonists on retention latencies in the inhibitory avoidance task.
SR141716 (A), SR144528 (B) and GW6471 (C) did not affect retention latencies in the inhibitory avoidance task. Data represent mean ± SEM (n = 10–13 per group).
revealed a significant agonist effect (F1,34= 5.72, p= 0.02), a non-
significant antagonist effect (Vehicle or SR141716) (F1,34 = 3.81,
p = 0.06) and a significant treatment interaction (F1,34 = 4.99,
p = 0.03). Post hoc analysis indicated that rats administered
with WIN55,212-2 had retention latencies significantly longer
when compared with vehicle-treated rats (p < 0.01; Figure 3A)
or with rats co-administered with WIN55,212-2 and SR141716.
Thus, the enhancing effect on memory consolidation induced by
WIN55,212-2 is mediated by CB1 receptor activation.
In a second set of experiment we co-administered immediately
after the training of the inhibitory avoidance the memory-
modulating dose of WIN55,212-2 (1 mg/kg) with SR144528
(0.03 mg/kg). Average step-through latencies for all groups
during the training, before footshock and drug administration,
were 13.71 ± 1.10 s. One-way ANOVA for training latencies
revealed no significant differences among groups (F3,41 = 1.63,
p = 0.02). At testing, retention latencies of rats given vehicle
immediately after the training were significantly longer than
their approach latencies during the training trial (t = −2.55,
p = 0.2), showing that the rats acquired the task. Interestingly,
retention latencies analyzed by two-way ANOVA revealed a
significant agonist or antagonist effect (F1,41 = 14.63, p= 0.0004;
F1,41 = 4.70, p = 0.04, respectively), but not a significant
treatment interaction (F1,41 = 1.75, p = 0.19). Post hoc analysis
showed that rats co-treated with vehicle and WIN55,212-2
had longer retention latencies that rats given vehicle alone or
vehicle and SR144528 together (p < 0.05; Figure 3B). Thus,
the enhancing effect on memory consolidation induced by
WIN55,212-2 depends not only CB1 receptor activation but
requires CB2 receptor activation as well.
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FIGURE 3 | Effects of post-training administration of WIN55,212-2 after concurrent administration with CB1 or CB2 antagonists on retention
latencies in the inhibitory avoidance task. The enhancing effect on retention latencies induced by WIN55,212-2 1 mg/kg was reverted by co-administration of
WIN55,212-2 1 mg/kg with: (A) SR141716 (0.3 mg/kg); (B) SR144528 (0.03 mg/kg). Data represent mean ± SEM. ∗p < 0.05 vs. vehicle-treated rats; #p < 0.05 vs.
WIN55,212-2+SR144528; ##p < 0.01 vs. WIN55,212-2+SR141716 (n = 9–12 per group).
Enhancement of Inhibitory Avoidance
Retention Performances Induced by
URB597 Requires Concomitant
Activation of both CB1 and CB2
Receptors
In these experiments we examined whether the enhancing effect
on retention latencies induced by URB597 could depend on
activation of cannabinoid receptors. In a first set of experiment we
co-administered immediately after the training of the inhibitory
avoidance the memory-modulating dose of URB597 (0.2 mg/kg)
with SR141716 (0.3 mg/kg). Average step-through latencies
for all groups during the training, before footshock and drug
administration, were 12.43 ± 1.92 s. One-way ANOVA for
training latencies revealed no significant differences among
groups (F3,41 = 0.56, p= 0.64).
At testing, retention latencies of vehicle-treated were
significantly longer than their approach latencies during the
training trial (t= –3.54, p= 0.005), showing that the rats retained
the memory of the footshock received during the training.
Interestingly, retention latencies analyzed by two-way ANOVA
revealed a significant effect of URB597 (F1,41 = 5.21, p = 0.03),
a non-significant SR141716 effect (F1,41 = 1.55, p = 0.22) and a
non-significant treatment interaction (F1,41 = 1.72, p = 0.22).
Post hoc analysis indicated that rats administered with vehicle
and URB597 had retention latencies significantly longer when
compared with vehicle-treated rats (p < 0.05; Figure 4A) but
they did not significantly differ from rats co-administered with
URB597 and SR141716. However, retention latencies of rats
treated with URB597 and SR141716 were comparable to the
latencies of controls. Thus, the enhancing effect on memory
consolidation induced by URB597 is only partially dependent
on CB1 receptor activation. In a second set of experiment we
co-administered immediately after the training of the inhibitory
avoidance the memory-modulating dose of URB597 (0.2 mg/kg)
with a dose not altering memory per se of SR144528 (0.03 mg/kg).
Average step-through latencies for all groups during the training,
before footshock and drug administration, were 11.60 ± 1.24 s.
One-way ANOVA for training latencies revealed no significant
differences among groups (F3,38 = 2.54, p= 0.07).
At testing, retention latencies of rats given vehicle immediately
after the training were significantly longer than their approach
latencies during the training trial (t = −6.14, p < 0.0001),
showing that the rats acquired the task. Retention latencies
analyzed by two-way ANOVA revealed a significant URB597
effect (F1,38 = 4.80, p = 0.03), but not a significant SR144528 or
interaction effect (F1,38 = 1.41, p = 0.24; F1,38 = 0.93, p = 0.34,
respectively). Post hoc analysis indicated that rats administered
with vehicle and URB597 had retention latencies significantly
longer when compared with vehicle-treated rats (p < 0.05;
Figure 4B) even though they did not significantly differ from
rats co-administered with URB597 and SR144528. However, the
retention latencies displayed by rats treated with URB597 and
SR144528 were comparable to the latencies of control animals.
Thus, the enhancing effect on memory consolidation induced by
URB597 is also partially dependent on CB2 receptor activation.
Enhancement of Inhibitory Avoidance
Retention Performances Induced by
URB597 Requires PPAR-α Receptor
Activation
In this experiment we examined whether the enhancing effect
on retention latencies induced by URB597 could depend on
activation of PPAR-α receptors. We co-administered immediately
after the training of the memory-modulating dose of URB597
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FIGURE 4 | Effects of post-training administration of URB597 after concurrent administration with the CB1 and CB2 antagonists on retention
latencies in the inhibitory avoidance task. The enhancing effect on memory retention induced by URB597 0.2 mg/kg was reverted by blocking cannabinoid
receptor activity through co-administration with: (A) SR141716 (0.3 mg/kg); (B) SR144528 (0.03 mg/kg). Data represent mean ± SEM. ∗p < 0.05 vs. vehicle-treated
rats (n = 10–12 per group).
(0.2 mg/kg) with a dose not altering memory per se of
GW6471 (1 mg/kg). Average step-through latencies for all groups
during the training, before footshock and drug administration,
were 12.20 ± 1.20 s. One-way ANOVA for training latencies
revealed no significant differences among groups (F3,43 = 1.52,
p = 0.22). At testing, retention latencies of rats given vehicle
were significantly longer than their approach latencies during the
training trial (t =−2.94, p= 0.01), showing that the rats retained
the memory of the footshock received during the training.
Retention latencies analyzed by two-way ANOVA revealed a
significant URB597 effect (F1,43 = 4.13, p = 0.04), but not a
significant SR141716 or interaction effect (F1,43 = 1.72, p= 0.20;
F1,43 = 1.45, p = 0.24, respectively). Post hoc analysis indicated
that rats administered with vehicle and URB597 had retention
latencies significantly longer when compared with vehicle rats
(p < 0.05; Figure 5A) but they did not significantly differ from
rats co-administered with URB597 and GW6471. However, at
the same time the difference between rats given vehicles and
rats given URB597 and GW6471 is not statistically significant.
Thus, the enhancing effect on memory consolidation induced
by URB597 could be partially dependent on PPAR-α receptor
activation.
Enhancement of Inhibitory Avoidance
Retention Performances Induced by
URB597 Requires Activation of TRPV1
Receptors
In this experiment we examined whether the enhancing effect
on retention latencies induced by URB597 could depend on
activation of TRPV1 receptors. We co-administered immediately
after the training of the memory-modulating dose of URB597
(0.2 mg/kg) with a dose not altering memory per se of capsazepine
(5 mg/kg). Average step-through latencies for all groups during
the training, before footshock and drug administration, were
15.67 ± 1.39 s. One-way ANOVA for training latencies revealed
no significant differences among groups (F3,42 = 1.27, p= 0.30).
At testing, retention latencies of vehicle-treated rats were
significantly longer than their approach latencies during the
training trial (t = −6.48, p < 0.0001), showing that the
rats retained the memory of the footshock received during
the training. Retention latencies analyzed by two-way ANOVA
revealed a significant URB597 effect (F1,42 = 5.55, p = 0.02), a
non-significant capsazepine effect (F1,42 = 0.84, p = 0.36) and
a non-significant treatment interaction (F1,43 = 0.91, p = 0.35).
Post hoc analysis indicated that rats administered with vehicle
and URB597 had retention latencies significantly longer when
compared with vehicle-treated rats (p < 0.05; Figure 5B) but
they did not significantly differ from rats co-administered with
URB597 and capsazepine. However, no statistically significant
difference was found between rats given vehicle and rats given
URB597 and capsazepine. Therefore, we can hypothesize that the
enhancing effect on memory consolidation induced by URB597
could also partially require TRPV1 receptor activation.
DISCUSSION
The present findings show that direct activation of cannabinoid
receptors, or pharmacological-induced potentiation of the
endocannabinoid tone, both enhance memory consolidation
for aversive experiences. We provide the first demonstration
that these effects are not only mediated by the activation of
CB1 receptors, but that CB2 receptors are also involved. We
further show that TRPV1 and PPAR-α receptors are involved in
mediating endocannabinoid effects on memory.
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FIGURE 5 | Effects of post-training administration of URB597 after concurrent administration with PPAR-α or TRPV1 antagonists on retention
latencies. The enhancing effect on retention latencies induced by URB597 0.2 mg/kg was partially reverted by blocking PPAR-α (A) or TRPV1 (B). Data represent
mean ± SEM. ∗p < 0.05 vs. vehicle-treated rats (n = 10–12 per group).
The memory facilitation effect induced by WIN55,212-2 and
the FAAH inhibitor URB597 is in line with previous studies
showing that WIN55,212-2 or URB597 induce in rats, through a
CB1-dependent signaling, enhancing effects when locally infused
into the basolateral complex of the amygdala (BLA), into the
hippocampus and into the prefrontal cortex immediately after
the training of an inhibitory avoidance task (Campolongo
et al., 2009b; Morena et al., 2014). However, opposite effects
have been reported after systemic or central administration
of cannabinoid agonists. For instance, it has been shown that
systemic administration of WIN55,212-2 or URB597 attenuated
memory consolidation in rats and mice exposed to different
cognitive tasks (Mackowiak et al., 2009; Busquets-Garcia et al.,
2011; Galanopoulos et al., 2014; Hasanein and Teimuri Far,
2015; Kruk-Slomka et al., 2016a). Similarly, post-training central
activation of cannabinoid receptors induced an amnesic response
in rats exposed to the Inhibitory Avoidance, contextual fear
conditioning, Morris Water Maze or object recognition tasks
(Clarke et al., 2008; Moshfegh et al., 2011; Segev and Akirav, 2011;
Hasanein and Sharifi, 2015). However, other reports demonstrate
that administration of the CB1 antagonist AM251 immediately
after training, induced similar effects to those induced by
agonists on the consolidation of memory in the inhibitory
avoidance or contextual fear conditioning tasks (Bucherelli
et al., 2006; Campolongo et al., 2009b). Several confounding
variables could be responsible for these apparent discrepancies.
Among them, the different experimental context/conditions, the
drug selectivity, the vehicle used for drug dissolution and the
time of administration are of crucial importance (Haller et al.,
2004a; Varga et al., 2008; Campolongo et al., 2012, 2013; Kruk-
Slomka et al., 2016b). For instance, following a pre-training
administration, cannabinoid compounds could strongly interfere
with pain perception (Burston and Woodhams, 2014) and/or
locomotor activity at the time of training (Martin and Lichtman,
1998). Moreover, each type of behavioral task could activate
distinctive neural substrates. Together with the extensive and
heterogeneous pattern of cannabinoid receptor expression at
brain level all these elements might explain the differences in
the effect induced by systemic or local infusion of cannabinoid
drugs.
Up-to-date the cognitive effects of synthetic or endogenous
cannabinoids have been considered as mostly mediated by
CB1 receptors expressed in the nervous system and CB2
receptors expressed in the immune system (Devane et al.,
1988; Matsuda et al., 1990; Munro et al., 1993). However,
recent evidence indicates that CB2 receptors are also expressed
in the brain. CB2 receptors (proteins or mRNA) have been
found in various areas of the central nervous system, such as
the brainstem, pons, cerebellum, cerebral cortex, hippocampus,
amygdala, striatum, substantia nigra, thalamus, hypothalamus
and olfactory bulb (Svizenska et al., 2008; Atwood and Mackie,
2010). Immunostaining studies demonstrated that CB2 receptors
are widely expressed in the soma and dendrites of pyramidal
cells and in some interneurons in the hippocampus (Gong
et al., 2006; Onaivi et al., 2006; Brusco et al., 2008), as
well as in microglia (Svizenska et al., 2008; Atwood and
Mackie, 2010). In the dendrites of hippocampal neurons,
CB2 receptors locate near synaptic contacts (Solowij et al.,
2002; Onaivi et al., 2006; Brusco et al., 2008). Despite the
role of CB1 receptors in the regulation of neurophysiological
functions has been extensively characterized, the presence of CB2
receptors in the brain is a novel finding, and their functional
significance remain to be clarified. Electrophysiological and
morphological studies strongly suggest that CB2 receptors
are involved in synaptic transmission and plasticity (Li and
Kim, 2016). Consequently, it has been demonstrated that
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CB2 receptors also modulate neurophysiological functions and
behaviors such as anxiety (Garcia-Gutierrez et al., 2012),
impulsive behaviors (Navarrete et al., 2012), vomiting (Van
Sickle et al., 2005), and pain (Jhaveri et al., 2007; Anand et al.,
2009; Han et al., 2013). It has been also demonstrated that
CB2 receptor knockout, knock-down or overexpression induce
phenotypes resembling those seen in several neuropsychiatric
disorders (Onaivi et al., 2008; Racz et al., 2008; Busquets-
Garcia et al., 2011; Ortega-Alvaro et al., 2011; Aracil-Fernandez
et al., 2012; Romero-Zerbo et al., 2012; Garcia-Gutierrez et al.,
2013), while blocking endocannabinoid degradation reduces
anxiety via CB2 receptor activation (Busquets-Garcia et al.,
2011).
Brain CB1 and CB2 receptors can be both activated by
cannabinoids. Anandamide and 2-AG, both substrates for
FAAH enzymes (Bisogno et al., 2002), act as full agonist
and partial agonist, respectively (Mackie and Hille, 1992;
Mechoulam et al., 1995; Showalter et al., 1996; Sugiura et al.,
2000), with a 3- to 4-fold higher affinity for the CB1 than
for the CB2 receptor (Mechoulam et al., 1995; Showalter
et al., 1996). 19-THC, the main psychoactive constituent of
Cannabis sativa, binds to CB1 and CB2 receptors with the
same affinity (Showalter et al., 1996). So that, it is tentative to
hypothesize that when the levels of endogenous cannabinoids
are elevated, or after marijuana consumption, both CB1 and
CB2 receptors could be differentially recruited to contribute to
the effects of (endo)cannabinoid on memory. Based on these
premises, in the present work, we systemically administered
different cannabinoid compounds immediately after inhibitory
avoidance training. We found that immediate post-training
administration of URB597 induced facilitates memory retention.
Not only the CB1 antagonist SR141716 but, interestingly,
also the CB2 antagonist SR144528 abolished this effect, thus
demonstrating that the URB597-induced facilitation of memory
consolidation requires a concurrent activation of both CB1 and
CB2 receptors.
It is known that several cannabinoid compounds could
activate not only CB1 and CB2 receptors but also PPARα
(Fu et al., 2003; Bouaboula et al., 2005; O’Sullivan, 2007;
Campolongo et al., 2009a; Luchicchi et al., 2010) and
TRPV1 receptors (Zygmunt et al., 1999; Svizenska et al.,
2008; Di Marzo and De Petrocellis, 2010). Here we show that
URB597 exerts its effect on memory consolidation by additionally
activating PPAR-α and TRPV1 as well. It should be taken into
account that FAAH, besides anandamide, hydrolyses other
N-acylethanolamines, such as palmitoylethanolamide (PEA)
and oleoylethanolamide (OEA) (Bisogno et al., 2002), which in
turn activate PPARs receptors. PPARs are a nuclear hormone
receptor family of and their target genes are involved in the
maintenance of both metabolism and energy homeostasis,
inflammation, and cell differentiation (Friedland et al.,
2012; Menendez-Gutierrez et al., 2012; Neher et al., 2012;
Poulsen et al., 2012; Alexander et al., 2015). In the last decade,
growing evidence showed that PPARs are bound and activated
by endocannabinoids, endocannabinoid-like compounds,
phytocannabinoids and synthetic cannabinoid postulating
a potential roles for PPAR activation in the physiological
effects of cannabinoids (Liu et al., 2003; O’Sullivan, 2007;
O’Sullivan et al., 2012). Although there is limited evidence
concerning the role of PPAR-α on memory and cognition,
our results are in line with previous studies showing that
systemic administrations of OEA, URB597, or WY14643 (a
PPAR-α agonist) facilitate learning processes and enhance
retention of inhibitory avoidance task through activation of
PPAR-α (Campolongo et al., 2009a; Mazzola et al., 2009).
Luchicchi et al. (2010) reported that URB597 specifically
modulates neuronal responses to different substances of
abuse through actions on both PPAR-α receptors and
cannabinoid CB1 receptors, suggesting that the fatty acid
ethanolamides anandamide, OEA, and PEA are engaged in
the modulation of neurophysiological and behavioral effects,
at least for addictive drugs. Several models on the potential
mechanisms of cannabinoid/PPAR interactions have been
proposed: (1) cannabinoids could bind directly to PPARs and
be converted into PPAR-active metabolites; (2) activation of
cell surface cannabinoid receptors could trigger intracellular
signaling cascades that lead to an indirect activation of
PPARs; (3) cannabinoids may be actively transported to the
nucleus by intracellular lipid binding proteins, the Fatty
Acid Binding Proteins (FABPs), to interact with PPAR-α
(Hughes et al., 2015; O’Sullivan, 2016). Further investigations
are needed in order to clarify which of the mechanisms
described above might be involved in the potentiation
of memory consolidation driven by cannabinoid/PPAR
interaction.
The present results further show that not only CB and PPARs
but also TRPV1 receptors are involved in the potentiation of
memory consolidation for aversive experiences. Anandamide
is a full agonist of TRPV1 (Zygmunt et al., 1999), and
emerging evidence strongly suggests that anandamide signaling
modulates synaptic plasticity via post-synaptic TRPV1 activation
(Chavez et al., 2010; Grueter et al., 2010; Puente et al.,
2011; Chavez et al., 2014). Furthermore, anandamide inhibits
phasic endocannabinoid signaling via TRPV1 activation and
2-AG synthesis mediated by metabotropic glutamate receptor
activation (Maccarrone et al., 2008). It is known that TRPV1
are implicated in LTD and LTP in the hippocampus (Marsch
et al., 2007; Chavez et al., 2010; Bennion et al., 2011), and that
they modulate hippocampal-dependent memory in rats trained
in the fear conditioning and step-down inhibitory avoidance
tasks (Genro et al., 2012). Moreover, it has been reported that
TRPV1 receptors may participate in the modulation of emotional
states, as TRPV1-deficient mice when tested in the elevated
plus maze and dark-light box tasks showed less anxiety-like
behavior than wild-type littermate (Marsch et al., 2007). In vitro
and in vivo studies reported that the TRPV1 agonist capsaicin
both facilitated LTP and prevented spatial memory retrieval
deficit, while the selective antagonist capsazepine inhibited LTD
(Li et al., 2008). Moreover, Batista et al. (2015) reported that
anandamide produced anxiolytic-like effect via TRPV1 receptor
activation. Here we add to these observations the finding that
TRPV1 receptors participate in the modulation of memory
consolidation for emotional experiences exerted by cannabinoid
compounds.
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Taken together, the results of the present study show
that the facilitation of memory consolidation induced by
increased levels of endogenous cannabinoids is dependent
not only upon cannabinoid receptor activation but involves
multiple neurotransmission pathways. This evidence drives
beyond the classical hypothesis centered on the unique role of
CB1 receptors on memory modulation by cannabinoids, and
reveals new insights in the neural mechanisms of emotional
memory.
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